WO2008038304A3 - Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger. - Google Patents

Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger. Download PDF

Info

Publication number
WO2008038304A3
WO2008038304A3 PCT/IN2007/000436 IN2007000436W WO2008038304A3 WO 2008038304 A3 WO2008038304 A3 WO 2008038304A3 IN 2007000436 W IN2007000436 W IN 2007000436W WO 2008038304 A3 WO2008038304 A3 WO 2008038304A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
nitric oxide
glucosidase inhibitor
oxide scavenger
formulation
Prior art date
Application number
PCT/IN2007/000436
Other languages
French (fr)
Other versions
WO2008038304A2 (en
Inventor
Jegannathan Srinivas
Original Assignee
Jegannathan Srinivas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jegannathan Srinivas filed Critical Jegannathan Srinivas
Publication of WO2008038304A2 publication Critical patent/WO2008038304A2/en
Publication of WO2008038304A3 publication Critical patent/WO2008038304A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A therapeutic formulation comprising of Alphaglucosidase Inhibitors as active agents namely, Acarbose and Miglitol, characterized in that said Alphaglucosidase Inhibitors are combined or complexated with NO Scavenger to prevent Diabetic Complications arising out of Nitrosative stress.
PCT/IN2007/000436 2006-09-26 2007-09-26 Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger. WO2008038304A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1761CH2006 2006-09-26
IN1761/CHE/2006 2006-09-26

Publications (2)

Publication Number Publication Date
WO2008038304A2 WO2008038304A2 (en) 2008-04-03
WO2008038304A3 true WO2008038304A3 (en) 2008-05-22

Family

ID=39230688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000436 WO2008038304A2 (en) 2006-09-26 2007-09-26 Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger.

Country Status (1)

Country Link
WO (1) WO2008038304A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013115742A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Pharmaceutical composition comprising alpha-glucosidase inhibitor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011066A1 (en) * 1996-09-10 1998-03-19 Medinox, Inc. Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
WO1998055453A1 (en) * 1997-06-04 1998-12-10 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor
WO1999066924A1 (en) * 1998-06-23 1999-12-29 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
US20020151540A1 (en) * 2000-05-05 2002-10-17 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
WO2005027981A1 (en) * 2003-09-17 2005-03-31 Board Of Regents, The University Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011066A1 (en) * 1996-09-10 1998-03-19 Medinox, Inc. Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
WO1998055453A1 (en) * 1997-06-04 1998-12-10 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor
WO1999066924A1 (en) * 1998-06-23 1999-12-29 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
US20020151540A1 (en) * 2000-05-05 2002-10-17 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
WO2005027981A1 (en) * 2003-09-17 2005-03-31 Board Of Regents, The University Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy

Also Published As

Publication number Publication date
WO2008038304A2 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
NZ590727A (en) Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
HK1125039A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
WO2010039538A3 (en) Flavivirus inhibitors and methods for their use
WO2008127975A3 (en) Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
WO2007095618A3 (en) Benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
WO2011123719A3 (en) Use of faah inhibitors for treating abdominal, visceral and pelvic pain
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
WO2010150995A3 (en) Compositions for treating drug addiction and improving addiction-related behavior
EP2086531A4 (en) Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
WO2011085162A3 (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
WO2007075695A3 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2009079451A3 (en) Compositions and methods of promoting wound healing
EP2671891A3 (en) Ang-2 inhibition to treat multiple sclerosis
WO2007095615A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatmentof pain
WO2008156550A3 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
WO2012064667A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
WO2009158031A3 (en) Methods and compositions for therapeutic treatment
WO2012154122A3 (en) A topical formulation for treatment of hyperkeratotic skin
WO2008070859A3 (en) Treatment of skin conditions by dickkopf1 (dkk1)
WO2011049327A3 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
WO2010059554A3 (en) Composition and method for treatment of bruising
EP3061824A3 (en) Organic compositions to treat beta-enac-related diseases
WO2009043170A8 (en) Treatment of dissection, aneurysm, and atherosclerosis using granzyme b inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07827585

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 22-09-2009

122 Ep: pct application non-entry in european phase

Ref document number: 07827585

Country of ref document: EP

Kind code of ref document: A2